Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice.
Takeuchi T, Maeta K, Ding X, Oe Y, Takeda A, Inoue M, Nagano S, Fujihara T, Matsuda S, Ishigaki S, Sahashi K, Minakawa EN, Mochizuki H, Neya M, Sobue G, Nagai Y.
Takeuchi T, et al. Among authors: maeta k.
Mol Ther Nucleic Acids. 2023 Jan 16;31:353-366. doi: 10.1016/j.omtn.2023.01.006. eCollection 2023 Mar 14.
Mol Ther Nucleic Acids. 2023.
PMID: 36817728
Free PMC article.